Healthcare Delivery
Our advocacy promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
EPHA #A2MDialogues
A series of online, live, public dialogues putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe.
Publications
Unleashing meaningful innovation through regulatory reform
Joint position paper on the Pharmaceutical Strategy for Europe
EPHA Position on Medicine Shortages
Latest Developments
The revision of the EU pharmaceutical legislation: balancing between innovation incentives and access to affordable medicines
Public consultation response highlighting critical aspects for the forthcoming revision of the pharmaceutical legislation.
How the Oslo Medicines Initiative can tackle the ever-increasing prices for medicines and vaccines
Speech given by EPHA’s Director General Dr. Milka Sokolović on better access to medicines within the Oslo Medicines Initiative.
EPHA joins calls for enhanced clinical trial transparency and good governance in the European Medicines Agency
EPHA has joined the call led by the European Alliance for Responsible R&D and Affordable Medicines to urge EU Ministers to ensure that the Regulation for a reinforced EMA role leads to enhanced clinical trial transparency and upholds good governance
Analysis & Opinion
European Parliament’s special committee on COVID-19 is an opportunity to drive health equity forward
Examining lessons learned and formulating recommendations for the new COVID committee within the EP.
Market mechanisms cannot be the solution to global health threats
COVID-19 was a test scenario for how we rise to global threats where the risk and impacts are unequally distributed.
The Slovenian Presidency of the EU and access to medicines: What’s next?
Analysis of the 2021 Council Conclusions and their potential role in the upcoming EU general pharma review.
